gestern +20% heute +15% +++AMARIN+++ - 500 Beiträge pro Seite

[mirox]

bin seit längerem hier investiert,
es gibt keine Nachrichten, der Kurs zieht ab.
Was ist los?

[liebes]

guck dir halt den chart an...

[jojobada]

Viel spass damit, bei circa 2,60 bis 2,75 weg damit!

Gap Close bei ca. 3,25 in USA



jojo

[mirox]

den chart kenne ich gut. Möchte gern wissen was ist die Ursache für den Kursanstieg!?

[mirox]

heute sind es bereits 500% in 6 Wochen
abkassieren oder laufen lassen (wäre mein zweiter "tender" = 1000% innerhalb von 2 Monaten)


MIRX

[mirox]

heute +40%

[mirox]

zwischenzeitlich war ich +400% in Plus,
jetzt wieder runter,
das ist lustig und macht Spaß!

[mirox]

bin ich hier der Alleinunterhalter?
macht nichts, die Schaukel macht Spaß!
heute wieder mehr als +10%

[mirox]

alles klar?


Amarin meldet positive Phase II-Resultate


Das Biotechnologieunternehmen Amarin Corp. hat positive Daten zu den Phase II-Versuchen mit dem Präparat Miraxion zur Behandlung von Depressionen erzielt. Wie das Unternehmen am Mittwoch weiter mitteilte, ergab eine Analyse zu zwei Studien eine wesentliche Verbesserung des Zustandes durch Miraxion für eine Untergruppe von Patienten mit spezifischen Symptomen.


Amarin geht davon aus, dass Patienten mit jener Art von Symptomen rund 20-30% sämtlicher Depressions-Patienten umfassen. Ende 2004 wurde ein Antrag auf Patentzuteilung eingereicht. Die weitere Vorgangsweise sieht im Jahresverlauf eine vollständige Veröffentlichung der Studienresultate vor.

[mirox]

Amarin meldet positive Phase III
!!!!!!!!

[mirox]

Hoffnung für Patienten mit schweren Depressionen?

Miraxion, ein halbsynthetisches, hoch gereinigtes Derivat der dreifach ungesättigten Eicosapentaensäure (EPA), hat in einer Phase-II-Studie bei der Behandlung von Patienten mit schweren Depressionen positive Ergebnisse erzielt, wie das Biotechnologieunternehmen Amarin meldete.

Miraxion wurde als Monotherapiepräparat bei 77 Patienten in einer klinischen Phase-II-Studie getestet. Die Probanden wiesen zu Beginn dieser Behandlung schwere melancholisch-vegetative Symptome auf und sprachen auf herkömmliche Medikamente nicht mehr an. Es wird geschätzt, dass ungefähr 20 bis 30% aller Patienten mit Depressionen unter dieser schweren Form leiden. Wie die Analysen der Studie ergaben, konnten nach sechswöchiger Behandlung der Patienten mit Miraxion erste positive Veränderungen der Symptome verzeichnet werden. Die vollständigen Resultate der Phase-II-Monotherapiestudie werden von Amarin noch im Laufe dieses Jahres erwartet.


Wirkmechanismus ungeklärt
Der Wirkmechanismus von Miraxion bei der Behandlung der schweren Depression ist noch nicht genau bekannt. Er unterscheidet sich jedoch von dem der typischen und atypischen Antidepressiva und selektiven Serotonin-Wiederaufnahmehemmer. Es wird angenommen, dass die Symptome und der Grad der Schwere der Depression im Zusammenhang mit einem starken Ungleichgewicht zwischen Eicosapentaensäure und Arachidonsäure stehen, in das Miraxion ausgleichend eingreift.


Bereits in einer Phase-III-Studie wurde der Wirkstoff bei der Behandlung der Huntington-Krankheit (Veitstanz) getestet, bei der es aufgrund erblich bedingter Genmutationen zu fortschreitenden Veränderungen des Gehirns bis hin zur Demenz kommt. Hier wird ein anderer Wirkmechanismus vermutet: Miraxion schein an der Stabilisierung der Mitochondrien der degenerativen Neurone beteiligt zu sein, wodurch der schleichende Zelltod aufgehalten oder verhindert wird. Für diese Indikation befindet sich Miraxion schon in der Zulassung: in den USA hat es den Fast-track-Status erhalten und in Europa und den USA den Orphan-drug-Status.


Mitte des Jahres liegen die Ergebnisse vor. Und diese können nicht mehr schlecht ausfallen.
Die Patentanmeldung ist sei Dez04 in Arbeit.
lg
MIRX

2005 -OUTLOOK
Miraxion in HDFinalize protocol Commence Phase III trials by mid 2005Miraxion in Depression Further data analysis from completed depression studies Seek U.S. & EU partnerExpand PipelineCommence an additional clinical program in 2005 in another indication from internal pipeline or in-licensing/acquisitionReduce dependency on Miraxion

[cyberhai]

Amarin hat eine lächerliche MK im Verhältnis zu den Zukunftsaussichten, ich bin jetzt auch investiert und überlege derzeit, nochmals nachzukaufen.

Ist von Euch auch noch jemand dabei?

Gruß Cyberhai

[cyberhai]

Mirox, bist Du noch investiert?

Gruß Cyberhai

[mirox]

logo, bin dabei. Amarin hat immer noch super Verträge, die in schlechten Zeiten das Fortführen der Forschung garantieren.
...ist eine meiner "tender"-Aktien.
lg
MIRX

[cyberhai]

Freut mich, dann sind wir hier wenigstens zu zweit, kam mir schon ganz alleine vor

Gruß Cyberhai

[cyberhai]

Amarin Receives Special Protocol Assessment From FDA for two Pivotal Phase III Clinical Trials for Miraxion in Huntington`s Disease
Monday September 12, 8:15 am ET

LONDON, September 12 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN - News) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure for the design of two pivotal Phase III clinical trials of Miraxion(TM) (ultra-pure ethyl-EPA) in Huntington`s disease. The Special Protocol Assessment (SPA) is a process under which the FDA provides evaluation and guidance on clinical trial protocols for Phase III trials.

ADVERTISEMENT
click here
Rick Stewart, Chief Executive Officer of Amarin, commented; "Reaching agreement with the FDA on the trial designs is a positive development for Amarin. This is a major milestone for the company and we look forward to immediate enrollment in the U.S. trial."

The U.S. and European trials will be multi-centre, randomized, double blind, placebo -controlled studies of Miraxion at 43 sites in the U.S. and up to 28 sites in Europe. The trials are expected to involve a total of up to 540 Huntington`s disease patients with approximately 300 in the U.S. Phase III trial and approximately 240 in the European Phase III trial over a 6 month period. Patients in the U.S. trial will participate in a further 6-month extension period.

The Huntington Study Group (H.S.G.), based at the University of Rochester, will conduct the U.S. clinical trial on behalf of Amarin. The H.S.G. is a non-profit group of physicians and other health care providers from medical centers in the U.S., Canada, Europe and Australia, experienced in the care of Huntington`s disease patients and dedicated to clinical research of Huntington`s disease. The European clinical trial will be conducted in collaboration with EURO-HD and ICON, a leading contract research organization (CRO). EURO-HD is a non-profit group of physicians and other healthcare professionals dedicated to the research and care of Huntington`s disease patients.

The primary endpoint of the trials will be to determine whether Miraxion taken 2 grams per day (1gram twice daily) results in clinically and statistically significant changes in the Total Motor Score-4 subscale of the Unified Huntington`s Disease Rating Scale (UHDRS).

Gruß Cyberhai

[cyberhai]

Amarin Shares Up As FDA OKs Study Design
Monday September 12, 11:48 am ET
Amarin Shares Rise After FDA OKs Clinical Trial Design for U.S. Huntington`s Disease Study

NEW YORK (AP) -- Shares of Amarin Corp. PLC surged Monday after the British drug developer said Monday that it will begin enrolling patients in a U.S. late-stage clinical trial immediately for its Huntington`s disease treatment.

ADVERTISEMENT
[-51395]
Amarin shares rose 13 cents, or 9.2 percent, to $1.55 in morning trading on the Nasdaq. The stock has gradually fallen from a 52-week high of $4.35 in November, after climbing from a low of 50 cents last September, and is down about 43 percent so far this year.

The company received a special protocol assessment from the Food and Drug Administration, where the agency evaluates and guides a drug maker through clinical trial design, for its Phase III evaluation of treatment candidate Miraxion. About 300 people will be enrolled in the United States and about 240 in Europe. European patients will participate in a six-month study, while U.S. patients will be followed for a year.

Huntington`s disease is a degenerative genetic brain disease without a cure or treatment. About 200,000 people in the United States are at risk of developing the disease between ages 30 and 50. The disease slowly diminishes a person`s cognitive and motor skills and can also cause emotional and behavioral problems.

The primary endpoint of the studies will be to see if Miraxion taken twice a day will significantly improve motor skills and disease ratings on a Huntington`s Disease scale.

Gruß Cyberhai

[betaberg]

Amarin wurde jetzt auch im letzten Global Biotech Investing empfohlen. Was meint ihr, ist die jetzt ein Kauf? Der Chart sieht nach einem Ausbruch aus!

[cyberhai]

Schwer zu beurteilen, Institutionelle sind bisher so gut wie gar nicht in Amarin investiert. Global Biotech Investing hat in letzter Zeit richtig gut mit seinen Empfehlungen gelegen. Ziel muss es sein, bereits investiert zu sein, bevor die Großen einsteigen, dann hat man bei positivem Verlauf der weiteren Medikamentenentwicklung einen Vervielfacher. Ich bleibe investiert (habe allerdings einen Teil von meiner ursprünglich sehr großen Position aus Gewichtungsgründen verkauft).

Gruß Cyberhai

[cyberhai]

Amarin Announces Significant Neuroprotective Effects of Miraxion
Wednesday November 16, 7:01 am ET

LONDON, November 16 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN - News) today announces that its ongoing pre-clinical research programs with the Institute of Neuroscience at Trinity College, Dublin have achieved important results in two specific areas of research, both concerning the mechanism of action and properties of Miraxion (ultra-pure ethyl-EPA). Firstly, the effect of Miraxion on modulation of neuro inflammation and secondly, the corresponding impact of Miraxion on the reduction of microglial activation.

- In aging brains Miraxion has been found to demonstrate neuro anti-inflammatory effects, consequently protecting the brain from inflammation which is often associated with a number of neurodegenerative diseases such as Alzheimer`s, Parkinson`s and Huntington`s disease.

- Age-related learning and memory decline in the brain has also been shown to be accompanied by inflammatory changes, typified by microglial activation. These changes are also accompanied and possibly triggered by an increase in pro-inflammatory cytokines and a decrease in protective cytokines.

- The full results of the studies on the neuroprotective effects of Miraxion will be presented today at the 35th Annual Society for Neuroscience meeting in Washington D.C. by Professor Marina Lynch and her associates from the Institute of Neuroscience at Trinity College, Dublin.

- Amarin also announces today that it has extended its research collaboration with the Institute of Neuroscience at Trinity College. The three year collaboration will focus on the further elucidation of the neuroprotective effects of Miraxion, Amarin`s lead compound. The project will also investigate potential follow-on compounds as part of Miraxion`s life cycle management program. Amarin is currently developing Miraxion in phase III clinical trials for Huntington`s disease and has completed several phase II trials in depressive disorders.

Commenting on the results of the studies, Rick Stewart, Chief Executive Officer of Amarin said, "Our long term commitment to neurology research has resulted in these important findings. Determining how Miraxion actually functions in the brain and establishing that Miraxion has neuroprotective effects is fundamental to our understanding of its mechanism of action in neurodegenerative diseases and depressive disorders. We look forward to the presentation of the study results at the 35th Annual Society for Neuroscience meeting in Washington."

Results of Pre-Clinical Studies

Evidence from the Institute of Neuroscience at Trinity College has consistently shown that the age-related decline in synaptic and cognitive function is accompanied by impairment in one form of synaptic plasticity, long-term potentiation (LTP) in the hippocampus, which is considered to be a possible biological substrate for both learning and memory. This impairment is coupled with inflammatory changes, typified by increased microglial activation, increased IL-1beta concentration and increased IL-1beta-induced cell signaling. These changes are accompanied by, and possibly triggered by, an increase in interferon-gamma (IFNgamma) and decreased concentration of the anti-inflammatory cytokines, IL-4 and IL-10.

Two posters will be presented at the Society meeting:

1. Summary: Ultra-Pure Ethyl-EPA confers neuroprotection in the rat hippocampus

Evidence suggests that as the brain ages, a cytokine imbalance develops: pro-inflammatory cytokine concentration increases (e.g. IL-1beta) whereas anti-inflammatory cytokine concentration decreases (e.g. IL-4 and IL-10). It was investigated if ultra-pure ethyl-EPA could modulate the inflammatory status in the aged rat hippocampus.

The results indicate:

a) Ultra-pure ethyl-EPA demonstrates anti-inflammatory effects which are mediated by down regulating pro-inflammatory cytokines (IL-1beta) in the brain, and up regulating anti-inflammatory cytokine (IL-4);

b) The increase in IL-4, an anti-inflammatory cytokine, was mediated by peroxisome proliferator activated receptor (PPARgamma) activation; Ultra-pure ethyl-EPA has previously been identified as an endogenous activator of PPARgamma.

2. Summary: Ultra-Pure Ethyl-EPA reduces the age-related increase in microglial activation in the adult hippocampus

Activated microglia are the primary source of the pro-inflammatory cytokine IL-1beta in the brain. Therefore it might be predicted that evidence of microglial activation will accompany the age-related increase in hippocampal IL-1beta concentration. The authors report that the aged brain is more vulnerable to insult, such as that induced by beta amyloid (Abeta), than the young brain, probably because of the age-related underlying inflammation.

The results indicate:

a) Ultra-pure ethyl-EPA reduced the age-related increase in microglial activation in the hippocampus;

b) This underlying inflammatory state significantly contributes to the exaggerated effects of Abeta in the aged rat, and ultra-pure ethyl-EPA treatment attenuates the Abeta-induced impairment in long term potentiation and the concurrent increase in IL-1beta concentration.

Professor Marina Lynch and her associates at Trinity College have published several papers in the past supporting the mechanism of action of Miraxion. Key papers that have been published in prestigious peer reviewed journals include:

Lonergan, P. E., Martin, D. S., Horrobin, D. F., and Lynch, M. A. Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus. J Neurochemistry 2004; 91: 20-9.

Martin D. D., Lonergan P. E., Boland B., Fogarty M. P., Brady M., Horrobin D. F., Campbell V. A. et al. Apoptotic changes in the aged brain are triggered by IL-1beta -induced activation of p38 and reversed by treatment with eicosapentaenoic acid. J Biological Chemistry 2002; 27739-46: 34239-34246.

Lonergan, P. E., Martin, D. S., Horrobin, D. F., and Lynch, M. A. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma -irradiation. J Biological Chemistry 2002; 277: 20804-20811.


Gruß Cyberhai

[Buddah]

[lion_hasser]

mensch - wenn ich die jetzt bloss shorten könnte - cyberhai, die amis sind durchgeknallt...

ich shorte virtuell 10000 stück und cover in genau 1 woche